Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists

Bull Exp Biol Med. 2008 Jun;145(6):696-9. doi: 10.1007/s10517-008-0172-9.

Abstract

Chronic treatment with opioid receptor ligands: nonselective peptide opioid receptor agonist dalargin (intraperitoneally in a dose of 1 mg/kg), selective nonpeptide kappa-receptor agonist GR 89696 (subcutaneously in a dose of 0.03 mg/kg), nonselectrive nonpeptide antagonist quadazocine (subcutaneously in a dose of 3 mg/kg) or naltrexone (subcutaneously in a dose of 10 mg/kg) for 20 day had no effect of the incidence of ischemic ventricular arrhythmias and the size of necrotic zone after coronary occlusion and reperfusion in rats in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azocines / pharmacology
  • Enkephalin, Leucine-2-Alanine / analogs & derivatives
  • Enkephalin, Leucine-2-Alanine / pharmacology
  • Heart / drug effects*
  • Heart / physiopathology
  • Male
  • Myocardial Reperfusion Injury / prevention & control*
  • Naltrexone / pharmacology
  • Narcotic Antagonists*
  • Piperazines / pharmacology
  • Pyrrolidines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Opioid / agonists*
  • Receptors, Opioid, delta / agonists
  • Receptors, Opioid, delta / antagonists & inhibitors
  • Receptors, Opioid, kappa / agonists
  • Receptors, Opioid, kappa / antagonists & inhibitors
  • Receptors, Opioid, mu / agonists
  • Receptors, Opioid, mu / antagonists & inhibitors

Substances

  • Azocines
  • Narcotic Antagonists
  • Piperazines
  • Pyrrolidines
  • Receptors, Opioid
  • Receptors, Opioid, delta
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • GR 89696
  • Naltrexone
  • Enkephalin, Leucine-2-Alanine
  • enkephalin-Leu, Ala(2)-Arg(6)-
  • quadazocine